Capital International Investors Grows Stake in Eli Lilly and Company (NYSE:LLY)

Capital International Investors boosted its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 23.2% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,730,758 shares of the company's stock after buying an additional 1,645,222 shares during the quarter. Eli Lilly and Company makes up 1.3% of Capital International Investors' holdings, making the stock its 17th biggest holding. Capital International Investors owned approximately 0.92% of Eli Lilly and Company worth $6,740,272,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of LLY. Principal Financial Group Inc. grew its holdings in shares of Eli Lilly and Company by 5.3% during the third quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company's stock valued at $1,070,698,000 after buying an additional 60,306 shares during the last quarter. M&T Bank Corp grew its position in Eli Lilly and Company by 0.7% during the third quarter. M&T Bank Corp now owns 266,822 shares of the company's stock valued at $236,389,000 after buying an additional 1,867 shares during the period. Invst LLC grew its holdings in Eli Lilly and Company by 3.5% during the third quarter. Invst LLC now owns 5,552 shares of the company's stock valued at $4,918,000 after purchasing an additional 189 shares during the period. McIlrath & Eck LLC lifted its holdings in Eli Lilly and Company by 3.4% during the third quarter. McIlrath & Eck LLC now owns 481 shares of the company's stock valued at $426,000 after purchasing an additional 16 shares during the last quarter. Finally, Virtu Financial LLC lifted its stake in shares of Eli Lilly and Company by 111.7% during the 3rd quarter. Virtu Financial LLC now owns 6,531 shares of the company's stock valued at $5,786,000 after buying an additional 3,446 shares in the last quarter. Institutional investors own 82.53% of the company's stock.

Insider Activity at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the company's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the transaction, the chief accounting officer now owns 5,840 shares in the company, valued at approximately $4,778,521.60. This represents a 14.62 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.13% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on LLY. Cantor Fitzgerald began coverage on Eli Lilly and Company in a research note on Tuesday. They set an "overweight" rating and a $975.00 price objective on the stock. Guggenheim lowered their price objective on shares of Eli Lilly and Company from $973.00 to $928.00 and set a "buy" rating on the stock in a research report on Monday, April 14th. StockNews.com raised Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Friday, February 7th. Leerink Partners set a $950.00 target price on Eli Lilly and Company in a research note on Friday, January 17th. Finally, Berenberg Bank set a $970.00 price target on Eli Lilly and Company in a research note on Thursday, January 16th. Two investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. According to data from MarketBeat, Eli Lilly and Company has an average rating of "Moderate Buy" and an average price target of $1,017.00.

Eli Lilly and Company Stock Performance

Shares of LLY stock traded up $5.69 on Tuesday, reaching $823.71. The stock had a trading volume of 1,360,236 shares, compared to its average volume of 3,419,167. The stock has a market cap of $781.01 billion, a P/E ratio of 70.61, a price-to-earnings-growth ratio of 1.40 and a beta of 0.51. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The company has a 50 day simple moving average of $827.99 and a 200 day simple moving average of $818.92. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Equities research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.